Is ENANTA PHARMACEUTICALS INC (ENTA) Halal?
Shariah Screening — 5 Standards
Based on financial data from September 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 14.7% / 30% | 48.1% / 30% | 1.8% / 30% | 14.45% / 5% | ✗ NOT HALAL |
| DJIM | 14.7% / 33% | 48.1% / 33% | 1.8% / 33% | 14.45% / 5% | ✗ NOT HALAL |
| MSCI | 20.6% / 33% | 67.3% / 33% | 2.5% / 33% | 14.45% / 5% | ✗ NOT HALAL |
| S&P | 14.7% / 33% | 48.1% / 33% | 1.8% / 33% | 14.45% / 5% | ✗ NOT HALAL |
| FTSE | 20.6% / 33% | 67.3% / 33% | 2.5% / 50% | 14.45% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -60.5% | |
| Net Margin | -106.8% | |
| Return on Equity (ROE) | -60.0% | |
| Return on Assets (ROA) | -13.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$19M |
| Free Cash Flow | -$32M |
| Total Debt | $58M |
| Debt-to-Equity | 152.6 |
| Current Ratio | 4.4 |
| Total Assets | $281M |
Price & Trading
| Last Close | $12.51 |
| 50-Day MA | $13.41 |
| 200-Day MA | $11.07 |
| Avg Volume | 223K |
| Beta | 1.0 |
|
52-Week Range
$4.09
| |
About ENANTA PHARMACEUTICALS INC (ENTA)
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ENANTA PHARMACEUTICALS INC (ENTA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ENANTA PHARMACEUTICALS INC is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ENANTA PHARMACEUTICALS INC's debt ratio?
ENANTA PHARMACEUTICALS INC's debt ratio is 14.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 20.6%.
What are ENANTA PHARMACEUTICALS INC's key financial metrics?
ENANTA PHARMACEUTICALS INC has a market capitalization of $353M, and revenue of $65M. The company maintains a gross margin of 100.0% and a net margin of -106.8%. Return on equity stands at -60.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.